Chemexpress(SH:688131) Ren Min Wang·2025-09-26 03:20Core Insights - The biopharmaceutical industry is undergoing an "intelligent revolution" with AI technology enhancing drug development processes, allowing researchers to more accurately identify targets and design candidate molecules [2] - Shanghai Haoyuan Pharmaceutical Co., Ltd. has been integrating AI with drug development since 2021, creating a one-stop drug screening platform that significantly improves the efficiency of drug discovery [2][3] - The company has built a vast "ammunition library" for drug screening, utilizing over 80,000 diverse drug-like molecules, 18 million available screening compounds, and a customizable MegaUni library of 10 million compounds, along with a billion-scale DEL library [2][3] AI Integration in Drug Development - The drug screening platform features an "intelligent engine" that combines generative AI technology to overcome traditional design limitations and accelerate drug development [3] - The integration of AI enhances the accuracy of predicting compound activity, moving away from the inefficient "needle in a haystack" approach of testing thousands of compounds [3] - The company's AI strategy is comprehensive, involving collaboration across multiple fields, including partnerships with pharmaceutical companies for AI-assisted chemical synthesis and custom small molecule development [3][4] Manufacturing and Operational Efficiency - Haoyuan Pharmaceutical is exploring AI applications in manufacturing, focusing on process development to achieve coordinated growth across research, development, and manufacturing [4] - The company employs intelligent methods to integrate multidimensional business data, providing precise support for lean management decisions [4] - The use of multimodal AI technology aims to enhance operational efficiency and management levels by breaking down system barriers [4] Strategic Collaborations and Industry Support - On August 19, Haoyuan Pharmaceutical's subsidiary signed a strategic cooperation agreement with Shanghai Jiao Tong University, focusing on "AI + organoids + drug development" to streamline the entire chain from basic research to industrial incubation [4] - The collaboration aims to leverage the university's advanced organoid laboratory and the company's extensive compound library to create a next-generation AI-enabled intelligent drug screening system [4] - The national policies during the 14th Five-Year Plan period are fostering a supportive environment for the growth of the biopharmaceutical industry, positioning the company as both a beneficiary and a promoter of industry advancement [4][5]